IL287979A - Dosage regimens for administration of lag-3/pd-l1 bispecific antibody - Google Patents

Dosage regimens for administration of lag-3/pd-l1 bispecific antibody

Info

Publication number
IL287979A
IL287979A IL287979A IL28797921A IL287979A IL 287979 A IL287979 A IL 287979A IL 287979 A IL287979 A IL 287979A IL 28797921 A IL28797921 A IL 28797921A IL 287979 A IL287979 A IL 287979A
Authority
IL
Israel
Prior art keywords
lag
administration
bispecific antibody
dosage regimes
regimes
Prior art date
Application number
IL287979A
Other languages
English (en)
Hebrew (he)
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of IL287979A publication Critical patent/IL287979A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL287979A 2019-05-14 2021-11-10 Dosage regimens for administration of lag-3/pd-l1 bispecific antibody IL287979A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
IL287979A true IL287979A (en) 2022-01-01

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287979A IL287979A (en) 2019-05-14 2021-11-10 Dosage regimens for administration of lag-3/pd-l1 bispecific antibody

Country Status (12)

Country Link
US (1) US20220275092A1 (https=)
EP (1) EP3969477A1 (https=)
JP (1) JP2022533578A (https=)
KR (1) KR20220008316A (https=)
CN (1) CN114206939A (https=)
AU (1) AU2020275209A1 (https=)
BR (1) BR112021022831A2 (https=)
CA (1) CA3139003A1 (https=)
IL (1) IL287979A (https=)
MX (1) MX2021013943A (https=)
SG (1) SG11202112136RA (https=)
WO (1) WO2020229626A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7850884B2 (ja) * 2021-03-31 2026-04-24 メルス・ベー・フェー 新規多重特異性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物

Also Published As

Publication number Publication date
JP2022533578A (ja) 2022-07-25
WO2020229626A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04
US20220275092A1 (en) 2022-09-01
KR20220008316A (ko) 2022-01-20
CN114206939A (zh) 2022-03-18
EP3969477A1 (en) 2022-03-23
SG11202112136RA (en) 2021-11-29
BR112021022831A2 (pt) 2022-01-18
CA3139003A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
IL287979A (en) Dosage regimens for administration of lag-3/pd-l1 bispecific antibody
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
EP4003327A4 (en) Dosing regimens for oral complement factor d inhibitors
GB2594345B (en) Single dosage shampoo
SG11201912161SA (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
IL275708A (en) Preferred dosing regimens of G1T38
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
IL278889A (en) Dosing regimen for the treatment of PI3K-related disorders
PT3738800T (pt) Equipamento para distribuição de cola com múltiplos componentes sobre uma mistura granular, bem como procedimento para distribuição e utilização do equipamento
IL279127A (en) Dispensing devices for drug administration
IL281958A (en) Pharmaceutical preparations containing bispecific anti-CD37 antibodies
PT4058148T (pt) Regime de dosagem para agentes anti-bcma
IL289575A (en) nmda receptor modulators
IL281398A (en) A process for preparing a pharmaceutical coated solid dosage form
HK40071349A (en) Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
GB201914040D0 (en) Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GB202000318D0 (en) Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB201906807D0 (en) Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
PL3972905T3 (pl) Urządzenie dozujące do podawania produktu infuzyjnego
IL279128A (en) Dispensing devices for drug administration
GB201916947D0 (en) Dosage dispensing system
HK40049719A (en) Dosing regimen for the treatment of pi3k related disorders
HK40074182A (en) Dosing regimen for anti-dll3 agents
GB201800873D0 (en) Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
HK40076627A (en) Gel-chewable dosage form